QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: mol.108.049437v1 74/3/662    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Ekins, S. Articles by Mani, S. PubMed PubMed Citation Articles by Ekins, S. Articles by Mani, S.

Computational Discovery of Novel Low Micromolar Human Pregnane X Receptor Antagonists

Collaborations in Chemistry, Jenkintown, Pennsylvania (S.E.); Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (S.E.); Department of Pharmacology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey (S.E., V.K., N.A., W.J.W.); Bristol-Myers Squibb Company, Wallingford, Connecticut (M.S.); Division of Clinical Pharmacology (J.G.) and Biochemistry and Molecular Genetics (L.G.), University of Colorado Denver, School of Medicine, Aurora, Colorado; Department of Pharmacology, The University of Toledo College of Pharmacy, Toledo, Ohio (K.B.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York (S.M.)

Very few antagonists have been identified for the human pregnane X receptor (PXR). These molecules may be of use for modulating the effects of therapeutic drugs, which are potent agonists for this receptor (e.g., some anticancer compounds and macrolide antibiotics), with subsequent effects on transcriptional regulation of xenobiotic metabolism and transporter genes. A recent novel pharmacophore for PXR antagonists was developed using three azoles and consisted of two hydrogen bond acceptor regions and two hydrophobic features. This pharmacophore also suggested an overall small binding site that was identified on the outer surface of the receptor at the AF-2 site and validated by docking studies. Using computational approaches to search libraries of known drugs or commercially available molecules is preferred over random screening. We have now described several new smaller antagonists of PXR discovered with the antagonist pharmacophore with in vitro activity in the low micromolar range [S-p-tolyl 3',5-dimethyl-3,5'-biisoxazole-4'-carbothioate (SPB03255) (IC₅₀, 6.3 µM) and 4-(3-chlorophenyl)-5-(2,4-dichlorobenzylthio)-4H-1,2,4-triazol-3-ol (SPB00574) (IC₅₀, 24.8 µM)]. We have also used our computational pharmacophore and docking tools to suggest that most of the known PXR antagonists, such as coumestrol and sulforaphane, could also interact on the outer surface of PXR at the AF-2 domain. The involvement of this domain was also suggested by further site-directed mutagenesis work. We have additionally described an FDA approved prodrug, leflunomide (IC₅₀, 6.8 µM), that seems to be a PXR antagonist in vitro. These observations are important for predicting whether further molecules may interact with PXR as antagonists in vivo with potential therapeutic applications.

Address correspondence to: Dr. Sean Ekins, Collaborations in Chemistry, Jenkintown, PA 19046. E-mail: ekinssean{at}yahoo.com